145 related articles for article (PubMed ID: 38165683)
1. Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer.
Oaknin A; Ghamande SA; Kasamatsu Y; Gil-Martin M; Grau-Bejar JF; Garcia-Duran C; Sato M; Siddiqui A; Chaudhary SP; Vugmeyster Y; Hasegawa K
Clin Cancer Res; 2024 Mar; 30(5):975-983. PubMed ID: 38165683
[TBL] [Abstract][Full Text] [Related]
2. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors.
Barlesi F; Isambert N; Felip E; Cho BC; Lee DH; Peguero J; Jerusalem G; Penel N; Saada-Bouzid E; Garrido P; Helwig C; Locke G; Ojalvo LS; Gulley JL
Oncologist; 2023 Mar; 28(3):258-267. PubMed ID: 36571770
[TBL] [Abstract][Full Text] [Related]
3. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort.
Cho BC; Daste A; Ravaud A; Salas S; Isambert N; McClay E; Awada A; Borel C; Ojalvo LS; Helwig C; Rolfe PA; Gulley JL; Penel N
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32641320
[TBL] [Abstract][Full Text] [Related]
4. Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer.
Kang YK; Bang YJ; Kondo S; Chung HC; Muro K; Dussault I; Helwig C; Osada M; Doi T
Clin Cancer Res; 2020 Jul; 26(13):3202-3210. PubMed ID: 32299818
[TBL] [Abstract][Full Text] [Related]
5. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia.
Lin CC; Doi T; Muro K; Hou MM; Esaki T; Hara H; Chung HC; Helwig C; Dussault I; Osada M; Kondo S
Target Oncol; 2021 Jul; 16(4):447-459. PubMed ID: 33840050
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer.
Yoo C; Oh DY; Choi HJ; Kudo M; Ueno M; Kondo S; Chen LT; Osada M; Helwig C; Dussault I; Ikeda M
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461347
[TBL] [Abstract][Full Text] [Related]
7. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies.
Strauss J; Gatti-Mays ME; Cho BC; Hill A; Salas S; McClay E; Redman JM; Sater HA; Donahue RN; Jochems C; Lamping E; Burmeister A; Marté JL; Cordes LM; Bilusic M; Karzai F; Ojalvo LS; Jehl G; Rolfe PA; Hinrichs CS; Madan RA; Schlom J; Gulley JL
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33323462
[TBL] [Abstract][Full Text] [Related]
8. Phase I Study of the Bifunctional Fusion Protein Bintrafusp Alfa in Asian Patients with Advanced Solid Tumors, Including a Hepatocellular Carcinoma Safety-Assessment Cohort.
Doi T; Fujiwara Y; Koyama T; Ikeda M; Helwig C; Watanabe M; Vugmeyster Y; Kudo M
Oncologist; 2020 Sep; 25(9):e1292-e1302. PubMed ID: 32324927
[TBL] [Abstract][Full Text] [Related]
9. Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial.
Cho BC; Lee JS; Wu YL; Cicin I; Dols MC; Ahn MJ; Cuppens K; Veillon R; Nadal E; Dias JM; Martin C; Reck M; Garon EB; Felip E; Paz-Ares L; Mornex F; Vokes EE; Adjei AA; Robinson C; Sato M; Vugmeyster Y; Machl A; Audhuy F; Chaudhary S; Barlesi F
J Thorac Oncol; 2023 Dec; 18(12):1731-1742. PubMed ID: 37597750
[TBL] [Abstract][Full Text] [Related]
10. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial.
Paz-Ares L; Kim TM; Vicente D; Felip E; Lee DH; Lee KH; Lin CC; Flor MJ; Di Nicola M; Alvarez RM; Dussault I; Helwig C; Ojalvo LS; Gulley JL; Cho BC
J Thorac Oncol; 2020 Jul; 15(7):1210-1222. PubMed ID: 32173464
[TBL] [Abstract][Full Text] [Related]
11. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort.
Tan B; Khattak A; Felip E; Kelly K; Rich P; Wang D; Helwig C; Dussault I; Ojalvo LS; Isambert N
Target Oncol; 2021 Jul; 16(4):435-446. PubMed ID: 34009501
[TBL] [Abstract][Full Text] [Related]
12. Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial.
Spira A; Wertheim MS; Kim EJ; Tan B; Lenz HJ; Nikolinakos P; Rich PL; Jehl G; Machl A; Ito R; Gulley JL; Kopetz S
Oncologist; 2023 Feb; 28(2):e124-e127. PubMed ID: 36576431
[TBL] [Abstract][Full Text] [Related]
13. Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers.
Yoo C; Javle MM; Verdaguer Mata H; de Braud F; Trojan J; Raoul JL; Kim JW; Ueno M; Lee CK; Hijioka S; Cubillo A; Furuse J; Azad N; Sato M; Vugmeyster Y; Machl A; Bajars M; Bridgewater J; Oh DY; Borad MJ
Hepatology; 2023 Sep; 78(3):758-770. PubMed ID: 36999533
[TBL] [Abstract][Full Text] [Related]
14. Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1/TGFβRII agent: Current status.
Gameiro SR; Strauss J; Gulley JL; Schlom J
Exp Biol Med (Maywood); 2022 Jul; 247(13):1124-1134. PubMed ID: 35473390
[TBL] [Abstract][Full Text] [Related]
15. Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma.
Khasraw M; Weller M; Lorente D; Kolibaba K; Lee CK; Gedye C; I de La Fuente M; Vicente D; Reardon DA; Gan HK; Scott AM; Dussault I; Helwig C; Ojalvo LS; Gourmelon C; Groves M
Neurooncol Adv; 2021; 3(1):vdab058. PubMed ID: 34056607
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetic Analysis of Bintrafusp Alfa in Different Cancer Types.
Wilkins JJ; Vugmeyster Y; Dussault I; Girard P; Khandelwal A
Adv Ther; 2019 Sep; 36(9):2414-2433. PubMed ID: 31278692
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with advanced non-small cell lung cancer.
Rajan A; Abdul Sater H; Rahma O; Agajanian R; Lassoued W; Marté JL; Tsai YT; Donahue RN; Lamping E; Bailey S; Weisman A; Walter-Rodriguez B; Ito R; Vugmeyster Y; Sato M; Machl A; Schlom J; Gulley JL
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38485188
[TBL] [Abstract][Full Text] [Related]
18. Identification of
Spira A; Awada A; Isambert N; Lorente D; Penel N; Zhang Y; Ojalvo LS; Hicking C; Rolfe PA; Ihling C; Dussault I; Locke G; Borel C
Front Oncol; 2022; 12():981940. PubMed ID: 36568239
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the tumor microenvironment and anti-tumor efficacy of subcutaneous vs systemic delivery of the bifunctional agent bintrafusp alfa.
Ozawa Y; Hicks KC; Minnar CM; Knudson KM; Schlom J; Gameiro SR
Oncoimmunology; 2021 May; 10(1):1915561. PubMed ID: 33996267
[TBL] [Abstract][Full Text] [Related]
20. Radiolabelling and preclinical characterization of
Burvenich IJG; Goh YW; Guo N; Gan HK; Rigopoulos A; Cao D; Liu Z; Ackermann U; Wichmann CW; McDonald AF; Huynh N; O'Keefe GJ; Gong SJ; Scott FE; Li L; Geng W; Zutshi A; Lan Y; Scott AM
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3075-3088. PubMed ID: 33608805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
